| abstract |
THEY REFER TO COMPOUNDS OF FORMULA (I), WHERE: "A" IS OF PREFERENCE FENILO SUBSTITUTED BY F; "D" IS -X-R5 OR IS -CR6R7R8, WHERE: R5 AND R6 ARE CYCLOALKYL C3-C8 OR ARILO C6-C10, AMONG OTHERS, WHICH ARE OPTIONALLY FOUND WITH CF3, TRIFLUORMETOXOS, OR "X" IS C1-C8 ALKYLENE OR C1-C8 ALKYLENE OPTIONALLY BISUSTITUTED BY OH; R7 IS H or HALOGEN; R8 IS H, HALOGEN or AZIDO, AMONG OTHERS; OR R7 AND R8 FORM TOGETHER WITH THE ATOM OF C A CARBONYL; "E" IS OF PREFERENCE CYCLOPENTILE AND ISOPROPYL; R1 AND R2 TOGETHER TOGETHER A C1-C6 ALKYLENE CHAIN IN WHICH O, S, SO2 OR NR13 IS INTERLACED, WHERE R13 IS H, C1-C6 ALKYL, C1-C6 ACIL, BENCIL OR PHENYL; THE HETERO-CYCLE AND / OR BENZOCONDENSED RING (R1 / R2) SO FORMED IS REPLACED BY A CARBONYL, OR14 OR BY THE RADICAL OF FORMULA (i), AMONG OTHERS. IT ALSO REFERS TO THE PREPARATION PROCEDURE FOR (I), WHICH INCLUDES INTRODUCING THE SUBSTITUTES "D", WITH ORGANOMETALLIC REAGENTS IN INERT SOLVENTS, IN THE SENSE OF A GRIGNARD OR WITTING REACTION. THE COMPOUNDS OBTAINED ACT AS INHIBITORS OF THE CHOLESTEROL ESTER TRANSFER PROTEIN (PTCE), BEING USEFUL IN THE TREATMENT AND PREVENTION OF HYPERLIPOPROTEINEMIAS, DYSLIPIDEMIA, HYPERLIPIDEMIS AND ARTERY |